| payload |
{"created_at":"2026-04-11T03:10:51.104 {"created_at":"2026-04-11T03:10:51.104915+00:00","dedupe_key":"signal_enriched:discovery_sec_filing_delta:d1233cb81454380d","evidence_event_ids":["evt_bdb952067569"],"signal_type":"discovery_sec_filing_delta","source":"discovery_sec_filings","value":{"aggregator_url":"https://www.sec.gov/Archives/edgar/data/1636282/0001636282-26-000041.txt","as_of":"2026-04-11T03:10:51.104915+00:00","canonical_url":"https://www.sec.gov/Archives/edgar/data/1636282/0001636282-26-000041.txt","company":"Spyre Therapeutics, Inc.","enrichment":{"aggregator_url":"https://www.sec.gov/Archives/edgar/data/1636282/0001636282-26-000041.txt","article_chars":336,"article_truncated":false,"blocked_reason":null,"candidate_id":"sc_05dc592cd24d3ff7","canonical_host":"sec.gov","canonical_is_aggregator":false,"canonical_url":"https://www.sec.gov/Archives/edgar/data/1636282/0001636282-26-000041.txt","content_type":"text/plain","enriched_at":"2026-04-11T07:18:38.664939+00:00","extraction_method":"trafilatura","fetched_description":"","fetched_title":"Document","final_url":"https://www.sec.gov/Archives/edgar/data/1636282/0001636282-26-000041.txt","html_truncated":true,"paywall_likely":false,"publisher_domain":"sec.gov","publisher_resolution":"canonical_url","requested_url":"https://www.sec.gov/Archives/edgar/data/1636282/0001636282-26-000041.txt","source_event_id":"evt_bdb952067569","source_quality":"low","status_code":200,"version":"signal_enrichment_v2"},"form_type":"DEFA14A","fp":"b7a2fea53d78e0f8","kind":"sec_filing","published_at":"20260410","publisher_domain":"sec.gov","signal_understanding":{"analysis_basis":"article","claim_confidence":0.45000000000000007,"dates_mentioned":["2026-04-10","2026-04-11"],"entities":[{"asset_class":"equity","name":"Spyre Therapeutics, Inc.","relevance":"high","symbol":"","type":"issuer"}],"event_type":"listing","information_gaps":["No amendment number is provided (\"Amendment No. )\" is blank in the cleaned text).","No details are provided about what changed versus any prior filing state (no prior-known state or comparative content included).","No proxy agenda items, voting matters, directors/officers, or financial implications are included in the provided text excerpt.","The filing timestamp in the structured context (2026-04-11T03:10:51.104915+00:00) conflicts with the source summary date (Filed 20260410); the exact filing date/time cannot be confirmed from the excerpt alone."],"key_facts":["The document is a Schedule 14A proxy statement pursuant to Section 14(a) of the Securities Exchange Act of 1934.","The filing is labeled as an amendment (\"Amendment No. \").","The registrant named in the document is Spyre Therapeutics, Inc."],"numeric_claims":[],"primary_claim":"Spyre Therapeutics, Inc. filed Form DEFA14A (Schedule 14A proxy statement) on 2026-04-10/2026-04-11 (per provided metadata).","relevance_score":0.35,"sentiment":"neutral","source_quality":"low","summary":"Spyre Therapeutics, Inc. filed a Schedule 14A proxy statement amendment on Form DEFA14A. The provided text does not include the amendment number or any substantive proxy/disclosure details.","topics":["SEC filing","proxy statement","Schedule 14A","DEFA14A"]},"source":"sec_edgar","source_domain":"sec.gov","summary":"Form DEFA14A \u00b7 Spyre Therapeutics, Inc. \u00b7 Filed 20260410","ticker":"SYRE","tickers":["SYRE"],"title":"SYRE filed DEFA14A","url":"https://www.sec.gov/Archives/edgar/data/1636282/0001636282-26-000041.txt"}}... |